Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.90
-0.25 (-4.07%)
At close: Sep 18, 2024, 4:00 PM
5.92
+0.02 (0.34%)
After-hours: Sep 18, 2024, 4:47 PM EDT

Company Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.

The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.

The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.
Ardelyx logo
Country United States
Founded 2007
IPO Date Jun 19, 2014
Industry Biotechnology
Sector Healthcare
Employees 267
CEO Michael Raab

Contact Details

Address:
400 Fifth Avenue, Suite 210
Waltham, Massachusetts 02451
United States
Phone 510 745 1700
Website ardelyx.com

Stock Details

Ticker Symbol ARDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001437402
CUSIP Number 039697107
ISIN Number US0396971071
SIC Code 2834

Key Executives

Name Position
Michael G. Raab President, Chief Executive Officer and Director
Elizabeth A. Grammer Esq. Chief Legal and Administrative Officer and Secretary
Dr. Laura A. Williams M.D., M.P.H. Chief Medical Officer
Justin A. Renz CPA, MBA Chief Financial and Operations Officer
Robert Felsch Senior Vice President of Finance and Chief Accounting Officer
Caitlin Lowie Vice President of Corporate Communications and Investor Relations
Mike Kelliher Executive Vice President of Corporate Development and Strategy
Charon Spencer Sr. Chief Human Resources Officer
David P. Rosenbaum Chief Development Officer
Robert C. Blanks Chief Regulatory Affairs and Quality Assurance Officer

Latest SEC Filings

Date Type Title
Sep 11, 2024 144 Filing
Aug 27, 2024 144 Filing
Aug 26, 2024 144 Filing
Aug 16, 2024 144 Filing
Aug 12, 2024 144 Filing
Aug 12, 2024 8-K Current Report
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jul 29, 2024 144 Filing
Jul 15, 2024 144 Filing